期刊文献+

拉氧头孢对肠杆菌科细菌及厌氧菌的体外抗菌活性观察 被引量:12

The activity of moxalactam against Enterobacteriaceae and anaerobia in vitro
原文传递
导出
摘要 目的观察拉氧头孢对肠杆菌科细菌及厌氧菌的体外抗菌活性,并与其他抗菌药物进行比较,为临床合理应用拉氧头孢提供实验依据。方法根据美国临床和实验室标准协会(CLSI)(2014版)标准,采用琼脂稀释法和Etest法测定拉氧头孢及其他抗菌药物对491株临床分离的肠杆菌科细菌和厌氧菌的最低抑菌浓度(MICs值)。结果拉氧头孢对大肠埃希菌、肺炎克雷伯菌、变形杆菌、肠杆菌属及其他肠杆菌科细菌均具有较好的抗菌活性(包括ESBLs大肠埃希菌、肺炎克雷伯菌及变形杆菌),其MIC50范围均在0.25—4mg/L之间,MIC90范围均在0.5~8mg/L之间,敏感率均在90%以上;产ESBLs与非产ESBLs的肠杆菌科细菌对亚胺培南及美罗培南的敏感率均在90%以上;产ESBLs的大肠埃希菌、肺炎克雷伯菌、变形杆菌对哌拉西林/他唑巴坦和头孢哌酮/舒巴坦的敏感率分别为90%、68%、53%和76%、66%、76.6%;而非产ESBLs细菌对哌拉西彬他唑巴坦和头孢哌酮/舒巴坦的敏感率在均95%以上;肠杆菌属细菌及其他肠杆菌科细菌对哌拉西林/他唑巴坦的敏感率分别为80%、80%,对头孢哌酮/舒巴坦的敏感率分别为80%、76.7%。拉氧头孢对厌氧菌的MICs范围为≤0.064-〉256mg/L,MIC50为2mg/L,MIC90为64mg/L。结论拉氧头孢对产与不产ESBLs的肠杆菌科细菌以及厌氧菌均具有较好的体外抗菌活性。 Objective To observe the antibacterial activity of moxalactam against Enterobacteriaceae bacteria and anaerobic bacteria in vitro, and to compare with other antibacterial drugs, for providing experimental basis for the clinical application of moxalactam. Methods Minimum inhibitory concentrations (MICs) of moxalactam and other antibacterial agents against 491 Enterobacteriaceae spp. and anaerobic spp. collecting from clinical settings were determined by agar dilution methods and E-test strips according to the Clinical and Laboratory Standards Institute (CLSI) (2014). Results Moxalactam showed great antibacterial activity to Enterobacteriaceae spp. , including ESBLs-producing Escherichia coli, Klebsiella pneumoniae, and Proteus spp. , with the MIC50, MIC90, and susceptibility rates of 0. 25 - 4 mg/L, 0. 5 - 8 rag/L, and 〉 90%, respectively. The susceptibility rates of Enterobacteriaceae with ESBLs-producing or non-ESBLs-producing to imipenem and meropenem were both higher than 90%. The susceptibility rates of ESBLs-producing Escherichia coli, Klebsiella pneumoniae, and Proteus spp. to piperacillin/tazobactam and cefoperazone/sulbactam were 90%, 68%, 53% and 76%, 66%, 76. 6%, respectively, while the susceptibility rates of non-ESBLs-producing Escherichia coli,Klebsiella pneumoniae, and Proteus spp. were all more than 95% . The susceptibility rates of Enterobacter spp. and other Enterobacter to piperacillin/ tazobactam were 80% , 80% and that to cefoperazone/sulbactam were 80% , 76. 7% , respectively. The MICs range of moxalactam on anaerobic spp. was from ≤0. 064 to 〉256 mg/L,while MIC50 was 2 mg/L and MIC90 was 64 mg/L. Conclusions Moxalactam showed well activity against ESBLs-producing and non-ESBLs- producing Enterobacteriaceae and anaerobia.
出处 《中华医学杂志》 CAS CSCD 北大核心 2016年第18期1459-1464,共6页 National Medical Journal of China
关键词 拉氧头孢 体外抗菌活性 超广谱Β内酰胺酶 Moxalactam Antimicrobial activity Extended-spectrum β-lactamases(ESBLs)
  • 相关文献

参考文献14

  • 1胡付品,朱德妹,汪复,蒋晓飞,徐英春,张小江,张朝霞,季萍,谢轶,康梅,王传清,王爱敏,徐元宏,沈继录,孙自镛,陈中举,倪语星,孙景勇,褚云卓,田素飞,胡志东,李金,俞云松,林洁,单斌,杜艳,韩艳秋,郭素芳,魏莲花,吴玲,张泓,孔菁,胡云建,艾效曼,卓超,苏丹虹.2014年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志,2015,15(5):401-410. 被引量:727
  • 2曹钰然,梁旺,施耀国,张菁.抗厌氧菌药物PK/PD研究方法概述[J].中国抗生素杂志,2012,37(2):90-93. 被引量:4
  • 3于巧亚,王雪涛.临床厌氧菌的研究现状[J].世界最新医学信息文摘,2014,14(21):123-124.
  • 4唐文明.注射用拉氧头孢钠与甲硝唑注射液配伍的稳定性考察[J].抗感染药学,2015,12(6):827-829. 被引量:2
  • 5Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. Document M100-$24. Wayne, PA: CLSI; 2014.
  • 6Jones RN, Barry AL, Packer RR, et al. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the Cefoperazone- Sulbactam Combination [ J ]. J Clin Microbiol, 1987,25 ( 9 ) :1725-1729.
  • 7Pitout JDD, Laupland KB. Extended-spectrum [3-1actamase- producing Enterobacteriaceae: an emerging public-health conceru [ J]. Lancet Infect Dis, 2008,8 (2) : 159-166. DOI: 10. 1016/ S1473-3099 (08) 7004143.
  • 8Falagas ME, Karageorgopoulos DE. Extended-spectrum beta- lactamase-producing organisms [ J ]. J Hosp Infect, 2009,73 (4) : 345-354. DOI : 10. 1016/j. jhin. 2009.02. 021.
  • 9Pitout JD. Infections with extended-spectrum beta-lactamase- producing Enterobacteriaceae: changing epidemiology and drug treatment choices [ J ]. Drugs, 2010,70 ( 4 ) : 313-333. DOI : 10. 2165/11533040 4300000000-00000.
  • 10Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum[ beta I - lactamase producing escherichia coli: changing epidemiology and clinical impact[ J]. Curr Opin Infect Dis,2010,23 (5) :320-326. DOI : 10. 1097/qco. 0b013e3283398dcl.

二级参考文献68

  • 1张凤凯,李家泰,潘石,郝凤兰,陈杨.拉氧头孢对临床分离的1143株致病菌体外抗菌作用的研究[J].中国抗生素杂志,1994,19(3):221-229. 被引量:6
  • 2Ambrose P G, Bhavnani S M, Rubino C M, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore[J]. Clin Infect Dis, 2007, 44(1): 79-86.
  • 3Mckellar O A, Bruni S F S, Jones D G. Pharmacokinetic/ pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine[J]. J Vet Pharmacol Ther, 2004, 27(6): 503-514.
  • 4Liu P, Rand K H, Obermann H, et al. Pharmacokinetic- pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models[J]. Int J Antimierob Agents, 2005, 25(2): 120-129.
  • 5Schmidt S, Barbour A, Sahre M, et al. PK/PD: new insights for antibacterial and antiviral applications[J]. Curr Opin Pharmacol, 2008, 8(5): 549-556.
  • 6Scaglione F, Paraboni L. Pharmacokinetics/ pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens[J]. Int J Antimicrob Agents, 2008, 32(4): 294-U 19.
  • 7Czock D, Markert C, Hartman B, et al. Pharmacokinetics and pharmacodynamics of antimicrobial drugs[J]. Expert Opin Drug Metab Toxicol, 2009, 5(5): 475-487.
  • 8Mazzei T. The Pharmacokinetics and Pharmacodynamics of the carbapenems: focus on doripenem[J]. J Chemother, 2010, 22(4): 219-225.
  • 9Li C H, Kuti J L, Nightingale C H, et al. Population pharmacokinetics and pharmacodynamics of piperacillin/ tazobactam in patients with complicated intra-abdominal infection[J]. JAntimierob Chemother, 2005, 56(2): 388-395.
  • 10Seifert H, Dalhoff A. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study[J]. JAntimicrob Chemother, 2010, 65(11): 2405-2410.

共引文献749

同被引文献73

引证文献12

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部